GIPM
DMAC icon

G2 Investment Partners Management’s DiaMedica Therapeutics DMAC Stock Holding History

G2 Investment Partners Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-219,973
Closed -$640K – 64
2018
Q4 		$640K Buy
+219,973
New +$691K 0.27% 51

Other funds holding DMAC

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CHP
Cable Hill Partners Portland, Oregon $1.02B AUM 8.59% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
GCM
Gables Capital Management Miami, Florida $236M AUM 32.91% 1-Year Est. Return

G2 Investment Partners Management's DMAC Position: Q1 2019 in Review

G2 Investment Partners Management sold out of DiaMedica Therapeutics (DMAC) in Q1 2019, closing a stake of 219,973 shares — an estimated $640K sold.

G2 Investment Partners Management first reported a position in DMAC in Q4 2018 and held it in 1 quarter. The position peaked at $640K in Q4 2018. 11 funds tracked by Wall St. Rank hold DMAC as of Q1 2019.

  • G2 Investment Partners Management reported no remaining DiaMedica Therapeutics position as of Q1 2019 after selling out during the quarter.
  • G2 Investment Partners Management sold 219,973 DiaMedica Therapeutics shares in Q1 2019, an estimated $640K.
  • G2 Investment Partners Management first reported a position in DiaMedica Therapeutics in Q4 2018 and held it in 1 quarter.
  • G2 Investment Partners Management's DiaMedica Therapeutics position peaked at $640K in Q4 2018.
  • 11 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2019.

Based on G2 Investment Partners Management's 13F filing for Q1 2019, filed 15 May 2019.